Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European Countries [PDF]
Ophthalmology and Therapy, 2022 Introduction: The 0.19 mg fluocinolone acetonide (FAc) intravitreal implant delivers a continuous intravitreal corticosteroid dose for the treatment of refractory diabetic macular oedema (DMO).
Louis Arnould +2 more
exaly +5 more sources
Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema [PDF]
Journal of Ophthalmic Inflammation and Infection, 2019 Background A retrospective observational clinical study to evaluate the safety and effectiveness of the injectable 0.19-mg fluocinolone acetonide intravitreal implant (ILUVIEN) in the treatment of non-infectious uveitic macular edema.
Lea F. Weber +6 more
doaj +2 more sources
Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®) [PDF]
Therapeutic Advances in Ophthalmology, 2019 Introduction: Macular edema after central retinal vein occlusion is a common cause of vision loss. Upregulation of vascular endothelial growth factor and higher levels of inflammatory mediators have been involved in the pathogeny of the macular edema in ...
João Coelho +2 more
doaj +2 more sources
Recurrent Diabetic Macular Edema: What to Do [PDF]
Case Reports in Ophthalmology, 2017 Diabetic macular edema (DME) is a leading cause of blindness in the working population. Herein, we report the case of a patient with recurrent DME for about 6 years, uncontrolled by several medical and surgical treatments, that was successfully treated ...
Rita Santos Gonçalves +2 more
doaj +3 more sources
Correction: The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema. [PDF]
Eye (Lond), 2021 Background/Objectives: To investigate if the visual and anatomic response to the first dexamethasone implant (DEX) predicts the 12-month clinical outcome after shifting to fluocinolone acetonide (FAc) implant in patients with diabetic macular oedema (DMO).
Cicinelli MV +9 more
europepmc +3 more sources
Evaluation of fluocinolone acetonide 0.19 mg intravitreal implant in the management of birdshot retinochoroiditis [PDF]
British Journal of Ophthalmology, 2020 Purpose: To report treatment outcomes and efficacy of the fluocinolone acetonide 0.19 mg intravitreal implant (Iluvien) in controlling retinal and choroidal inflammation in 11 patients with birdshot retinochoroiditis.
Ajamil-Rodanes, S +5 more
core +5 more sources
Rapid Structural and Functional Improvements with the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Patients with DME and Low Visual Acuity: 6-Month Data from the UAE [PDF]
Clinical Ophthalmology, 2020 Ahmed Mohammed Elbarky1,2 1Vitreoretinal consultant, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates; 2Department of Ophthalmology, Benha Faculty of Medicine, Benha University, Benha, EgyptCorrespondence: Ahmed Mohammed Elbarky Email abarky ...
Elbarky AM
doaj +2 more sources
Intravitreal Fluocinolone Acetonide Implant (ILUVIEN®) for the Treatment of Retinal Conditions. A Review of Clinical Studies [PDF]
Drug Design, Development and Therapy, 2023 Fluocinolone acetonide (FAc) intravitreal implant (Iluvien®) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non– infectious ...
Georgios D Panos +5 more
core +5 more sources
Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema
Drug Design, Development and Therapy, 2013 Wyatt B Messenger, Robert M Beardsle, Christina J FlaxelCasey Eye Institute, Oregon Health and Science University, Portland, OR, USAAbstract: Diabetic macular edema (DME) remains one of the leading causes of moderate to severe vision loss. Although laser
Messenger WB, Beardsley RM, Flaxel CJ
doaj +6 more sources
Preliminary evaluation of YUTIQ™ (fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis. [PDF]
Ther Deliv, 2019 Uveitis is a major cause of ocular morbidity, potentially leading to significant visual impairment. The recent adoption of alternative drug delivery options has led to the development of new sustained-delivery corticosteroid systems, able to manage successfully chronic noninfectious posterior uveitis.
Testi I, Pavesio C.
europepmc +5 more sources